Provided are a preparation method of trophoblasts with limited generations, a culture method of SNK cells and a method for treating tumor. The preparation method of trophoblasts includes the following steps: ligating a TAX2 gene to a lentiviral expression vector, followed by transferring into competent cells to obtain a lentivirus containing the TAX2 gene; infecting PBMCs with the lentivirus containing the TAX2 gene and culturing, and collecting CD3-cells; ligating a 41BBL-MICA fusion gene to the lentiviral expression vector, followed by transferring into the competent cells to obtain a lentivirus containing the 41BBL-MICA fusion gene; and mixing the CD3-cells with the lentivirus containing the 41BBL-MICA fusion gene and culturing to obtain the trophoblasts with limited generations.

The present disclosure generally relates to, inter alia, recombinant immune cells that have been engineered to express elevated levels of one or more glucose transporters, and particularly relate to engineered immune cells exhibiting increased glycolytic flux and/or enhanced effector functions. Also provided are methods for generating a population of engineered immune cells with enhanced effector function, pharmaceutical compositions the same, as well as methods and kits for the prevention and/or treatment of a health condition in subjects in need thereof.

The disclosure relates to an anti-CD133 single-chain antibody. The amino acid sequence of the anti-CD133 single-chain antibody comprises a sequence shown in SEQ ID NO. 1. T lymphocytes expressing the anti-CD133 single-chain antibody can specifically kill CD133-positive tumor cells and have higher specificity and stronger killing ability.

The disclosure relates to an anti-TIM3 single-chain antibody. The amino acid sequence of the anti-TIM3 single-chain antibody is a sequence shown in SEQ ID NO. 1. T lymphocytes expressing the anti-TIM3 single-chain antibody can effectively kill tumor cells.

The disclosure features amphiphilic ligand conjugates comprising a chimeric antigen receptor (CAR)ligand and a lipid. The disclosure also features compositions and methods of using the same, for example, to stimulate proliferation of CAR expressing cells.

Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

The invention provides methods and compositions for use in treating cancer, which advantageously may be achieved by targeting of the tumor microenvironment.

The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.

The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.

The present invention relates to a method for producing natural killer cells using T cells, and more particularly, to a method for producing natural killer cells, which comprises culturing seed cells using CD4 (+) T cells as feeder cells. The method for producing natural killer cells using T cells according to the present invention is a method capable of producing natural killer cells by selectively proliferating only natural killer cells from a small amount of seed cells while maintaining the high killing activity of the natural killer cells. The method of the present invention can produce a large amount of natural killer cells that can be frozen, and thus is useful for commercialization of cell therapeutic agents.